Remus Pharmaceuticals Share Price
Start SIP in Remus Pharmaceuticals
Start SIPRemus Pharmaceuticals Performance
Day Range
- Low 2,460
- High 2,499
52 Week Range
- Low 1,088
- High 2,835
- Open Price2,471
- Previous Close2,411
- Volume8100
Remus Pharmaceuticals Investment Rating
-
Master Rating:
-
Remus Pharmaceuticals Ltd has an operating revenue of Rs. 212.50 Cr. on a trailing 12-month basis. An annual revenue growth of 44% is outstanding, Pre-tax margin of 15% is great, ROE of 29% is exceptional. The company has a reasonable debt to equity of 3%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 5% and 29% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 3% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 5 which is a POOR score indicating inconsistency in earnings, a RS Rating of 76 which is FAIR indicating the recent price performance, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 41 indicates it belongs to a fair industry group of Medical-Whlsle Drg/Suppl and a Master Score of B is close to being the best. Institutional holding has remained stable in the last reported quarter. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
Indicator | Mar 2024 | Mar 2023 |
---|---|---|
Total Revenue Annual Cr | 67 | 47 |
Operating Expenses Annual Cr | 43 | 34 |
Operating Profit Annual in Cr | 20 | 11 |
Depreciation Cr | 1 | 0 |
Interest Annual Cr | 0 | 0 |
Tax Annual Cr | 6 | 3 |
Net Profit Annual Cr | 17 | 9 |
Remus Pharmaceuticals Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 14
- Bearish Moving Average
- ___
- 2
- 20 Day
- ₹2,485.42
- 50 Day
- ₹2,352.90
- 100 Day
- ₹2,161.87
- 200 Day
- ₹1,881.66
- 20 Day
- ₹2,556.85
- 50 Day
- ₹2,303.93
- 100 Day
- ₹2,126.56
- 200 Day
- ₹1,863.20
Remus Pharmaceuticals Resistance and Support
Resistance | |
---|---|
First Resistance | 2,505.87 |
Second Resistance | 2,521.93 |
Third Resistance | 2,544.87 |
RSI | 52.27 |
MFI | 37.36 |
MACD Single Line | 60.04 |
MACD | 23.89 |
Support | |
---|---|
First Support | 2,466.87 |
Second Support | 2,443.93 |
Third Supoort | 2,427.87 |
Remus Pharmaceuticals Delivery and Volume
Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
---|---|---|---|
Day | 8,100 | 679,995 | 83.95 |
Week | 6,220 | 469,983 | 75.56 |
1 Month | 4,982 | 339,112 | 68.07 |
6 Month | 6,770 | 448,077 | 66.19 |
Remus Pharmaceuticals Result Highlights
Remus Pharmaceuticals Synopsis
NSE-Medical-Whlsle Drg/Suppl
Remus Pharmaceutic belongs to the Industry of Pharmaceuticals. Company’s Total Operating Revenue is Rs. 63.50 Cr. and Equity Capital is Rs. 1.47 Cr. for the Year ended 31/03/2024. Remus Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 21/09/2015 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is U24232GJ2015PLC084536 and registration number is 084536.Market Cap | 1,467 |
Sales | 63 |
Shares in Float | 0.17 |
No of funds | 3 |
Yield | 0.24 |
Book Value | 17.88 |
U/D Vol ratio | 1.6 |
LTDebt / Equity | 1 |
Alpha | 0.23 |
Beta | 1.25 |
Remus Pharmaceuticals Shareholding Pattern
Owner Name | Jun-24 | Mar-24 | Sep-23 |
---|---|---|---|
Promoters | 70.66% | 70.6% | 69.61% |
Foreign Portfolio Investors | 3% | 3.25% | 2.38% |
Individual Investors | 20.9% | 20.54% | 21.15% |
Others | 5.44% | 5.61% | 6.86% |
Remus Pharmaceuticals Management
Name | Designation |
---|---|
Mr. Swapnil Jatinbhai Shah | Chairman & Wholetime Director |
Mr. Arpit Deepakkumar Shah | Managing Director |
Mrs. Anar Swapnil Shah | Whole Time Director |
Ms. Roma Vinodbhai Shah | Whole Time Director |
Mr. Balwant Purohit | Ind. Non-Executive Director |
Mrs. Sanjana Sanjeev Shah | Ind. Non-Executive Director |
Mr. Vishrut Chandramauli Pathak | Ind. Non-Executive Director |
Remus Pharmaceuticals Forecast
Price Estimates
Remus Pharmaceuticals Corporate Action
Date | Purpose | Remarks |
---|---|---|
2024-05-16 | Audited Results | |
2024-04-23 | Bonus issue & Interim Dividend | |
2024-04-22 | Interim Dividend |
Date | Purpose | Remarks |
---|---|---|
2024-05-02 | INTERIM | Rs.0.00 2nd interim dividend of Rs. 4.00/- (Rupees Four only) per equity share having face value of Rs. 10/- each for the financial year 2023-24. |
2023-10-28 | INTERIM | Rs.0.00 Interim Dividend of Rs. 2 per equity share. |
Date | Purpose | Remarks |
---|---|---|
2024-06-06 | Bonus | Rs.0.00 issue in the ratio of 3:1 of Rs. 10/-. |
Remus Pharmaceuticals FAQs
What is Share Price of Remus Pharmaceuticals ?
Remus Pharmaceuticals share price is ₹2,489 As on 21 September, 2024 | 06:43
What is the Market Cap of Remus Pharmaceuticals ?
The Market Cap of Remus Pharmaceuticals is ₹1467 Cr As on 21 September, 2024 | 06:43
What is the P/E ratio of Remus Pharmaceuticals ?
The P/E ratio of Remus Pharmaceuticals is As on 21 September, 2024 | 06:43
What is the PB ratio of Remus Pharmaceuticals ?
The PB ratio of Remus Pharmaceuticals is 14.1 As on 21 September, 2024 | 06:43